Synthesis, anticancer and antimicrobial properties of some N-aryl-2-(5-aryltetrazol-2-yl)acetamides

Abstract: The synthesis, anticancer and antimicrobial properties of novel N-aryl-2-(5-aryltetrazol-2-yl)acetamides were discussed. Novel N-aryl-2H-tetrazoles were synthesized and modified in order to obtain the compounds with a satisfactory pharmacological profile. The structures of target substances were confirmed by using ¹H spectroscopy, mass spectrometry and elemental analysis. Anticancer activity screening was carried out within the framework of Developmental Therapeutic Program of the National Cancer Institute's (DTP, NCI, Bethesda, Maryland, USA). The compounds with significant levels of anticancer activities have been found that can be used for further optimization. The antimicrobial activity of the synthesized substances was evaluated by the value of the MIC and minimum fungicidal and bactericidal concentration. The findings exhibited that the compounds possessed moderate antimicrobial potential.

How to cite this paper

 Chaban, T., Rotar, D., Panasenko, N., Skrobala, V., Pokhodylo, N & Matiychuk, V. (2022). Synthesis, anticancer and antimicrobial properties of some N-aryl-2-(5-aryltetrazol-2-yl)acetamides.Current Chemistry Letters, 11(3), 299-308.

Refrences

1. Carugo A., Draetta G. (2019) Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. Annu. Rev. Cancer Biol. 3(1) 385-408.
2. Сheng G., Dai M., Ahmed S., Hao H., Wang X., Yuan Z. (2016) Antimicrobial Drugs in Fighting against Antimicrobial Resistance. Front. Microbiol. 7 470-481.
3. Chaban T., Arshad M., Kostyshyn L., Drapak I., Matiychuk V. (2021) Synthesis, molecular docking and antimicrobial activities 2-(1-allyl-1H-tetrazol-5-ylsulfanyl)-N-aryl-acetamides. Eur. Chem. Bull. 10 (4) 230-236.
4. Sofan M., Said S., Kandeel S. (2012) Antimicrobial Activity of Newly Synthesized Thiadiazoles, 5-benzyl-2H-tetrazole and Their Nucleosides. Der Pharma Chemica 4 (3) 1064-1073.
5. Wani M., Ahmad A., Aqlan F., Al-Bogami A. (2020) Azole based acetohydrazide derivatives ofcinnamaldehyde target and kill Candida albicans by causing cellular apoptosis. ACS Med. Chem. Lett. 11 (4) 566-574.
6. Wang S., Wang Y., Xu Z.(2019) Tetrazole hybrids and their antifungal activities. Eur. J. Med. Chem. 170 225-234.
7. Popova E. A., Trifonov R. E., Ostrovskii V. A. (2019) "Tetrazoles for biomedicine". Russ. Chem. Rev. 88 (6) 644-676.
8. Liu J., Ren Z., Fan Li., Wei J., Tang X., Xu X., Yang D. (2019) Design, synthesis, biological evaluation,structure-activity relationship, and toxicity ofclinafloxacin-azole conjugates as novel antitubercular agents. Bioorg. Med. Chem. 27 (1) 175-187.
9. Popova E., Mikolaichuk O., Protas A., Mukhametshin A., Ovsepyan G., Starova G., Suezov R., Fonin A., Trifonov R. (2018) Synthesis, Structure, and Antiproliferative Activity of trans-Palladium(II) Complexes with Tetrazol-2-ylacetic Acid Derivatives. Russ. J. Gen. Chem. 88 (11) 2354-2358.
10. Kothari P., Singh S., Parmar S., Stenberg V. (2009) Synthesis of some newer 5-(5-aryl-2H-tetrazol-2-ylmethyl)-4-substituted-s-triazole-3-thiols as possible antiinflammatory agents. J. Heterocycl. Chem. 17 (11) 1393-1398.
11. Reddy S., Surya S., Shaik M., Kanuparthy P. (2016) Copper complexes of pyridyl-tetrazole ligandswith pendant amide and hydrazide arms: synthesis, characterization, DNA-binding and antioxidant properties. Transit. Met. Chem. 41 (5) 517-523.
12. El-Sayed W., El-Kosy S., Ali O., Emselm H., Abdel-Rahman A. (2012) Anticancer activity of new (tetrazol-5-yl)methylindole derivatives and their acyclic C-nucleoside analogs. Acta Pol. Pharm. 69 (4), 669-677.
13. Upadhayaya R, Sinha N., Jain S., Kishore N., Chandra R., Arora S. (2004) Optically active antifungal azoles: synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-[2-[4-aryl-piperazin-1-yl]-ethyl]-tetrazol-2-yl/1-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol. Bioorg. Med. Chem. 12 (9) 2225-2238.
14. Sharma S., Kozek K., Abney K., Kumar S., Gautam N., Alnouti Y., Weaver C., Hopkins C. (2019) Discovery, synthesis and characterization of aseries of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as nove lGIRK1/2 potassium channel activators. Bioorg. Med. Chem. Lett. 29 (6) 791-796.
15. Kettle J., Anjum R., Barry E., Bhavsar D., Brown C., Boyd S., Campbell A., Goldberg K., Grondine M., Guichard S., Hardy C., Hunt T., Jones R., Li X., Moleva O., Ogg D., Overman R., Packer M., Pearson S., Schimpl M., Shao W., Smith A., Smith J., Stead D., Stokes S., Tucker M., Ye Y. (2018) Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. J. Med. Chem. 61 (19) 8797-8810.
16. Hrast M., Jukič M., Patin D., Tod J., Dowson C., Roper D., Barreteau H., Gobec S. (2018) In silico identification, synthesis and biological evaluation of novel tetrazole inhibitors of Mur B. Chem. Biol. Drug. Des. 91 (6) 1101-1112.
17. Dockendorff C., Faloon P., Germain A., Yu M., Youngsaye W., Nag P., Bennion M., Penman M., Nieland T., Dandapani S., Perez J., Munoz B., Palmer M., Schreiber S., Krieger M. (2015) Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg. Med. Chem. Lett. 25 (12) 2594-2598.
18. Yang C., Chen S., Zhou M., Li Y., Li Y., Zhang Z., Liu Z., Ba Q., Li J., Wang H., Yan X., Ma D., Wang, R. (2014) Development of 3-Phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide Compounds as Inhibitors of Antiapoptotic Bcl-2 Family Proteins. Chem.Med.Chem. 9 (7) 1436-1452.
19. Chaban T., Matiichuk Y., Сhulovska Z., Tymoshuk O., Chaban I. and Matiychuk V. (2021) Synthesis and biological evaluation of new 4-oxo-thiazolidin-2-ylidene derivatives as antimicrobial agents. Arch. Pharm. 354 (7) e2100037.
20. Pokhodylo N., Teslenko Y., Matiychuk V. and Obushak M. (2009) Synthesis of 2, 1-benzisoxazoles by nucleophilic substitution of hydrogen in nitroarenes activated by the azole ring. Synthesis. 16 2741-2748.
21. Chaban T., Matiichuk Y., Shyyka O., Chaban I., Ogurtsov V., Nektegayev I. and Matiychuk V. (2020) Synthesis, molecular docking and biological properties of novel thiazolo[4,5-b]pyridine derivatives. Acta Chim. Slov. 67 (4) 1035–1043.
22. Pokhodylo N.T., Matiychuk V.S., Obushak N.B.(2009) Synthesis of 1H-1,2,3-triazole derivatives by the cyclization of aryl azides with 2-benzothiazolylacetonone, 1,3-benzo-thiazol-2-ylacetonitrile, and (4-aryl-1,3-thiazol-2-yl)acetonitriles. Chem. Heterocycl. Compd. 45 (4) 483-488.
23. Matiichuk Y, Ostapiuk Y., Chaban T., Ogurtsov V. and Matiychuk V. (2020) Synthesis and anticancer properties of n-(5-r-benzyl-1,3-thiazol-2-yl)-2,5-dimethyl-3-furamides. Biopolym. Cell. 36 (1) 74–83.
24. Chaban T. and Matiychuk V. (2020) Synthesis of 2-aryl-5-oxo-5H-thiopyrano[4,3-b]pyridine-7-carboxylic acids as the first representatives of a new heterocyclic system. Russ. J. Gen. Chem. 90 (8) 1578–1580.
25. Tymoshuk O., Oleksiv L., Khvalbota L., Chaban T. and Patsay I. (2019) Spectrophotometric determination of Ru(IV) using 5-hydroxyimino-4-imino-1,3-thiazolidin-2-one as a novel analytical reagent. Acta Chim. Slov. 66 (1) 62–69.
26. Chaban T., Matiychuk V., Ogurtsov V., Chaban I. and Nektegayev I. (2020) Development of effective anti-inflammatory drug candidates among novel thiazolopyridines. Ukr. Biochem. J. 92 (2) 132–139.
27. Chaban T., Ogurtsov V., Mahlovanyy A., Sukhodolska N., Chaban I., Harkov S. and Matiychuk V. (2019) Antioxidant properties of some novel derivatives thiazolo[4,5-b] pyridine. Pharmacia. 66 (3) 171–180.
28. Сhulovska Z., Drapak I., Chaban T., Ogurtsov V. and Matiychuk V. (2021) Synthesis, anticancer and antioxidant properties of some 4-thioxo-thiazolidin-2-ones. Eur. Chem. Bull. 10 (3) 147–154.
29. Chaban T., Ogurtsov V., Chaban I., Myrko I., Harkov S. and Leluykh M. (2019) Synthesis of some new 4-iminothiazolidine-2-ones as possible antioxidants agents. Pharmacia 61 (1) 27–32.
30. Rydchuk P., Tymoshuk O., Oleksiv L., Chaban T. and Matiychuk V. (2019) Voltammetric Determination of Pt(IV) using 5-Hydroxyimino-4- imino-1,3-thiazolidine-2-one. Methods Objects Chem. Anal. 14 (3) 130–139.
31. Chaban T., Matiychuk V., Mahlovanyy A., Chaban I., Ogurtsov V. and Leluykh M. (2020) Synthesis and biological evaluation of 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea derivatives. Biointerface Res. Appl. Chem. 10 (4) 5944–5950.
32. Drapak I., Foliush V., Chaban T. and Matiychuk V. (2020) Synthesis antimicrobial and antitumor activities of 2-[5-(2-R-benzyl)thiazol-2-ylimino]thiazolidin-4-ones. Biointerface Res. Appl. Chem. 10 (3) 5507–5511.
33. Chaban T. Matiichuk Y., Horishny V., Chaban I. and Matiychuk V. (2020) Synthesis and anticancer activity of 2-aryl-3-methylbenzofuro[3,2-b]pyrazolo[4,3-e]azepine-4,11(2H,10H)-dione and 2-aryl-3,7,9-trimethylpyrido[3',2':4,5]thieno[3,2-b]pyrazolo[4,3-e]azepine-4,11(2H,10H)-diones. Russ. J. Org. Chem. 56 (5) 813–818.
34. Developmental Therapeutics Program. Available online: http://dtp.nci.nih.gov.
35. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. (1991) Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Nat. Cancer Inst. 83 (11) 757-766.
36. Boyd M. R., Paull K. D. (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34 (1) 91-109.
37. Shoemaker R. H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6 (10) 813-823.
38. Yakovychuk N., Deyneka S., Grozav A., Humenna A., Popovych V., Djuiriak V. (2018) Аntifungal activity of 5-(2-nitrovinyl) imidazoles and their derivatives against the causative agents of vulvovaginal candidiasis. Regul. Mech. Biosyst. 9 (3) 369-373.